Ulysses Diversified Holdings
545 8TH AVENUE, NEW YORK, NY, 10018, UNITED STATES
Overview
Ulysses Holdings develops, finances, and supports companies through investments and professional support.
- Total investments
- 4
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 0
Investment portfolio
- Alloy Therapeutics
Participated · Series E · Apr 2026
Alloy Therapeutics combines proprietary AI/ML, real-world data, and wet-lab execution to provide integrated discovery and development services across multiple biologic modalities, including antibodies, bispecifics, genetic medicines, TCRms, cell therapies, and drug delivery. Since its 2017 founding, Alloy has partnered with over 200 organizations, generated more than 100 licensed therapeutic programs, and advanced 22 programs into clinical development, with two programs in Phase 3. The company has expanded beyond discovery into pharmacology, preclinical and clinical development services, and biologics manufacturing, positioning itself as a full-stack biotech infrastructure provider. Alloy operates a distributed model with centers of excellence across the U.S., Japan, the Middle East, and other emerging markets. Financially, the company just raised $40 million in a Series E at a $1.0 billion valuation to scale its services and accelerate its AI/ML and data capabilities.
- Compass Therapeutics, Inc.
Participated · Series A · Jul 2018
Compass Therapeutics is a Cambridge, MA–based biotechnology company focused on developing antibody-based therapeutics that target the human immune synapse. The company employs antibody discovery and bispecific engineering platforms, including its proprietary StitchMabs high-throughput bispecific screening platform. StitchMabs enables rapid identification of synergistic bispecific activity across a broad range of epitopes on each target. Compass reports the ability to drug two new targets per month and to generate therapeutic candidates in less than two months from antigen to candidate set. It has more than 15 therapeutic candidates in preclinical development, has filed over 50 patent applications, and its lead immuno-oncology candidate, CTX-471, is in late IND-enabling studies and expected to enter the clinic in the first half of 2019. The company says the recent financing will enable advancement of its antibody-based therapeutics into the clinic.
- WelbeHealth
Led · Series B · Jun 2018
WelbeHealth delivers coordinated, value-based care to medically frail, Medicare-Medicaid eligible seniors through comprehensive Programs of All-Inclusive Care for the Elderly (PACE). The company leverages industry-leading technologies to support highly coordinated interdisciplinary care teams and a service-oriented approach to individual patients' health and social needs. WelbeHealth's model aims to keep patients in their homes and out of hospitals, nursing homes, and other care facilities. The team is led by co-founder and CEO Si France and was founded by a group of physician entrepreneurs; the company is Silicon Valley–based with Menlo Park, California cited in its filings. WelbeHealth plans to open its first PACE organization to serve the Stockton and Modesto, Calif. area, described as the largest region in California without a PACE program. Services to be provided include primary care, physical and occupational therapy, social services, and dentistry. WelbeHealth is a Silicon Valley–based healthcare services company founded by physician entrepreneurs to serve vulnerable seniors with higher-quality, compassionate, value-based care. It delivers coordinated, interdisciplinary care to medically frail seniors, leveraging industry-leading technologies to support care teams and address comprehensive health and social needs. The company is preparing to launch several value-based care models, including Programs of All-Inclusive Care for the Elderly (PACE), targeting high-risk, dual-eligible populations. Within PACE populations the article cites the average participant is 77 years old, has 15 medical conditions, and is impaired in several activities of daily living, underscoring the high acuity WelbeHealth targets. WelbeHealth will use the financing to develop its initial market and roll out new initiatives to improve the quality of care for seniors. The company announced a $15 million Series A led by F-Prime Capital and .406 Ventures.
Team
No current team members are available.